Editor's Note: This Manuscript was accepted for publication April 9, 2008. Supported by a grant from the Fondation Vésale (Brussels, Belgium) (to S.S., V.M.), and LMU excellent (to H.-J.G., S.A., H.K.). Christine Decaestecker is a Senior Research Associate with the Belgian National Fund for Scientific Research (FNRS, Brussels, Belgium).
Galectin-3 Upregulation During Tumor Progression in Head and Neck Cancer†
Version of Record online: 2 JAN 2009
Copyright © 2008 The Triological Society
Volume 118, Issue 9, pages 1583–1590, September 2008
How to Cite
Saussez, S., Decaestecker, C., Mahillon, V., Cludts, S., Capouillez, A., Chevalier, D., Vet, H. K., André, S., Toubeau, G., Leroy, X. and Gabius, H.-J. (2008), Galectin-3 Upregulation During Tumor Progression in Head and Neck Cancer. The Laryngoscope, 118: 1583–1590. doi: 10.1097/MLG.0b013e31817b0718
- Issue online: 2 JAN 2009
- Version of Record online: 2 JAN 2009
- squamous cell carcinoma
Objectives/Hypothesis: To examine the level of expression of galectin-3 in relation to neoplastic progression of hypopharyngeal squamous cell carcinomas (HSCCs) and laryngeal squamous cell carcinomas (LSCCs).
Study Design: Retrospective study.
Methods: Using a polyclonal antibody against galectin-3 without cross-reactivity to other galectins, we analyzed the presence of galectin-3 using quantitative immunohistochemistry in i) a series of 79 HSCCs compared with 16 normal epithelia, 20 low-grade dysplasia (Low_D) and 25 high-grade dysplasia (High_D) and in ii) a series of 58 LSCCs compared with 34 normal epithelia, 12 Low_D, and 18 High_D. In parallel, galectin-3 expression was studied using Western blotting on a series of 19 fresh biopsies from patients presenting a head and neck tumor.
Results: Western blotting excluded a notable degree of proteolytic truncation of galectin-3 in situ. Immunohistochemical galectin-3 positivity expressed as percentage of cells was significantly higher in LSCCs and HSCCs than in Low_D (P = .01) or High_D (P = .0002), respectively. Increased expression of galectin-3 in HSCCs was accompanied by a shift from the cytoplasmic compartment to the nucleus (P = .007). In intertumor-type comparison, laryngeal carcinomas presented nuclear presence of galectin-3 only rarely (1 of 58 cases in laryngeal cancer vs. 27 of 79 cases in hypopharyngeal cancer, P = .00006) and a comparatively low labeling index (P < 10−6).
Conclusions: Our data reveal an association between level of presence of galectin-3 and neoplastic progression of HSCCs and LSCCs.